Cellectis (CLLS) Operating Income (QoQ) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.04% |
| Dec 31, 2025 | -315.79% |
| Sep 30, 2025 | 183.88% |
| Jun 30, 2025 | 32.39% |
| Mar 31, 2025 | -32.76% |
| Dec 31, 2024 | 0.83% |
| Sep 30, 2024 | 37.43% |
| Jun 30, 2024 | 17.63% |
| Mar 31, 2024 | 29.36% |
| Dec 31, 2023 | -43.09% |
| Sep 30, 2023 | 12.49% |
| Jun 30, 2023 | -0.81% |
| Mar 31, 2023 | -313.98% |
| Dec 31, 2022 | 79.31% |
| Sep 30, 2022 | -0.15% |
| Jun 30, 2022 | 6.55% |
| Mar 31, 2022 | -19.01% |
| Dec 31, 2021 | 42.03% |
| Sep 30, 2021 | -13.04% |
| Jun 30, 2021 | -88.28% |
| Mar 31, 2021 | 49.17% |
| Dec 31, 2020 | -33.42% |
| Sep 30, 2020 | 11.13% |
| Jun 30, 2020 | -329.19% |
| Mar 31, 2020 | 137.44% |
| Dec 31, 2019 | -44.44% |
| Sep 30, 2019 | 24.13% |
| Jun 30, 2019 | -51.94% |
| Mar 31, 2019 | 21.00% |
| Dec 31, 2018 | -1.25% |
| Sep 30, 2018 | -33.22% |
| Jun 30, 2018 | 12.87% |
| Mar 31, 2018 | 10.30% |
| Dec 31, 2017 | -8.01% |
| Sep 30, 2017 | -29.49% |
| Jun 30, 2017 | -0.52% |
| Mar 31, 2017 | 2.83% |
| Dec 31, 2016 | -57.54% |
| Sep 30, 2016 | -13.97% |
| Jun 30, 2016 | 49.72% |
| Mar 31, 2016 | -1,801.52% |
| Dec 31, 2015 | 108.85% |
| Sep 30, 2015 | -11.61% |
| Jun 30, 2015 | -233.36% |